Informace o publikaci

Karyotype complexity and prognosis in acute myeloid leukemia

Autoři	STÖLZEL F. MOHR B. KRAMER M. OELSCHLÄGEL U. BOCHTLER T. BERDEL W.E. KAUFMANN M. BALDUS C.D. SCHÄFER-ECKART K. STUHLMANN R. EINSELE H. KRAUSE S.W. SERVE H. HÄNEL M. HERBST R. NEUBAUER A. SOHLBACH K. MAYER Jiří MIDDEKE J.M. PLATZBECKER U. SCHAICH M. KRÄMER A. RÖLLIG C. SCHETELIG J. BORNHÄUSER M. EHNINGER G.
Rok publikování	2016
Druh	Článek v odborném periodiku
Časopis / Zdroj	Blood Cancer Journal
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1038/bcj.2015.114
Obor	Onkologie a hematologie
Klíčová slova	HEMATOPOIETIC-CELL TRANSPLANTATION; PROSPECTIVE AML96 TRIAL; EUROPEAN LEUKEMIANET; MONOSOMAL KARYOTYPE; RECOMMENDATIONS; IMPACT; CLASSIFICATION; ABNL(17P); DIAGNOSIS; SYSTEM
Přiložené soubory	EL_1333758.pdf
Popis	A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p21~22;q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with greater than or equal to4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9;11)(p21~22;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.